Clinical Trials Logo

Insulin Resistance clinical trials

View clinical trials related to Insulin Resistance.

Filter by:

NCT ID: NCT05904509 Completed - Atopic Dermatitis Clinical Trials

Insulin Resistance in Atopic Dermatitis Patients

Start date: September 1, 2022
Phase:
Study type: Observational

The aim of the study is to determine the relationship between insulin resistance and disease duration and severity of atopic dermatitis.

NCT ID: NCT05902546 Completed - Diabetes Mellitus Clinical Trials

Effect of HIIT Vs Moderate Intensity Aerobic Exercise on Insulin Resistance in Type 2 DM

Start date: January 7, 2023
Phase: N/A
Study type: Interventional

Comparing between the efficacy of high intensity interval training and moderate intensity aerobic exercises on insulin resistance in type 2 Diabetes Mellitus.

NCT ID: NCT05898360 Recruiting - HEALTHY VOLUNTEERS Clinical Trials

Promoting Immune Health by Intermittent Fasting: a Pilot Study

TIGER
Start date: May 15, 2023
Phase: N/A
Study type: Interventional

The goal is to study the direct effects of long-term intermittent fasting on immune cell populations in the blood, combined with analyses of systemic metabolic fitness and inflammatory activation of leukocytes.

NCT ID: NCT05874635 Recruiting - Clinical trials for Diabetes Mellitus, Type 2

Signos DM2 Empowerment Study (SIGNOS-CGM-EMPOWER-201-2022)

Start date: May 11, 2023
Phase: N/A
Study type: Interventional

The use of continuous glucose monitoring (CGM) in earlier data has inspired behavioral changes leading to improved adherence to an exercise plan in individuals and eating habits in people with diabetes. Mobile health (mHealth) platforms provide satisfactory, easy-to-use tools to help participants in the pursuit of weight change goals. We hypothesize that the use of CGM data and the Signos mHealth platform will assist with weight control in a population of people with type 2 diabetes mellitus who are not using insulin.

NCT ID: NCT05868785 Recruiting - Osteoporosis Clinical Trials

Effect of Nocturnal Parenteral Nutrition on Bone Turnover and Energy Metabolism

NutriSync
Start date: July 13, 2023
Phase: N/A
Study type: Interventional

This clinical trial will study the effect of daytime versus nighttime parenteral nutrition on bone turnover, glucose variability, nitrogen balance, sleep and wake rhythm and peripheral clock gene expression in patients with chronic intestinal failure.

NCT ID: NCT05856877 Recruiting - Clinical trials for Diabetes Mellitus, Type 2

Central Insulin Sensitivity in Individuals With Type 2 Diabetes (T2D) and at Risk for Developing T2D

Start date: May 26, 2023
Phase: N/A
Study type: Interventional

Beside well described peripheral effects, insulin can also affect the human central nervous system. Centrally acting insulin seems to have an influence e.g. on whole-body metabolism and food intake. Targeting insulin receptors in the central nervous system can modulate peripheral insulin sensitivity as well as pancreatic insulin secretion. In humans, the effect of insulin can be measured in different brain areas as estimate of central nervous insulin sensitivity. Reduced central nervous insulin sensitivity, called "central insulin resistance," has been associated, for example, with obesity, unfavorable body fat distribution, and impaired cognitive functionality. Recently novel subtypes and risk clusters of diabetes and prediabetes have been identified. In this study the investigators want to investigate and compare central nervous insulin sensitivity as well as cognitive function in the different diabetes and prediabetes risk clusters.

NCT ID: NCT05853913 Recruiting - Obesity Clinical Trials

Acute Exercise on Brain Insulin Sensitivity

Start date: May 11, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

Dementia is a leading cause of death in the United States among aging adults. Brain insulin resistance has emerged as a pathologic factor affecting memory, executive function as well as systemic glucose control. Regular aerobic exercise decreases Alzheimer's Disease (AD) risk, in part, through changes in brain structure and function. However, there is limited data available on how exercise impacts brain insulin resistance in aging. This study will test the effect of acute exercise on brain insulin sensitivity in middle-aged to older adults. The study will also examine cognition and cardiometabolic health in relation to brain insulin sensitivity.

NCT ID: NCT05835999 Recruiting - Aging Clinical Trials

Everolimus Aging Study

EVERLAST
Start date: March 24, 2023
Phase: Phase 2
Study type: Interventional

The objective of this project is to determine if mTORC1 inhibition by 24 weeks of daily (0.5 mg/day) or weekly (5 mg/week) everolimus can safely improve physiological and molecular hallmarks of aging in humans. Participants who are 55-80 years old and insulin resistant or prediabetic will be randomized to treatment and can expect to be on study for up to approximately 38 weeks. Participants aged 18-35 will not receive the intervention and can expect to be on study for up to approximately 8 weeks.

NCT ID: NCT05833217 Not yet recruiting - Insulin Resistance Clinical Trials

Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2

Start date: May 2, 2023
Phase: N/A
Study type: Interventional

The investigators are studying the pathophysiologic links between obesity, insulin resistance (IR), adipose tissue infection, and post-acute sequelae of COVID-19 (PASC). This study looks at whether adipose (fat) tissue contributes to PASC by driving chronic inflammation or by serving as a reservoir for SARS-CoV-2 persistence. The results will not only determine whether obesity and IR are risk factors for PASC, but will also define fundamental biology that sets the stage for the investigation of novel or existing therapies that target the causal pathways identified.

NCT ID: NCT05818293 Recruiting - Insulin Resistance Clinical Trials

Effect of Radiofrequency on Insulin Resistence in Obese Post Menopansal Women

Start date: July 9, 2023
Phase: N/A
Study type: Interventional

insulin resistance as the prime factor linking visceral obesity with adverse metabolic changes. Analysis of abdominal obesity by imaging studies have generally reached the conclusion that it is the excess of intra-abdominal or visceral adipose tissue .Multiple environmental and genetic factors are thought to influence the manifestation of abdominal obesity. The expanded adipose tissue contributes to expose the liver to high concentrations of free fatty acids (FFA), impairing several hepatic metabolic processes leading to hyperinsulinemia .On the other side, there is an increase in the secretion of different adipokines, such as interleukin IL-6 and tumor necrosis factor-α (TNF-α), which also contributes to the insulin-resistant state . So, RF technology deployed by Vanquish uses oscillating electrical current forcing collisions between charged molecules and ions, which are then transformed into heat. Since fat biophysical characteristics behave like an insulator capable of polarization, it absorbs the high RF-related heat release from the RF applicator driving specific fat necrosis and consequent lipolysis. Patients lay underneath the device while the focused-field radiofrequency heats up the underlying .